PMID: 11913480Mar 27, 2002Paper

A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease

European Heart Journal
G BorianiVentricular Arrhythmias Dofetilide Investigators

Abstract

Antiarrhythmic drugs are still used for the treatment of ventricular tachyarrhythmias, in combination with implantable cardioverter-defibrillators or without them. In a double-blind randomized crossover design, the short- and long-term efficacy and safety of oral dofetilide or oral sotalol were compared in 135 patients with ischaemic heart disease and inducible sustained ventricular tachycardia. The inducibility of ventricular tachycardia was determined by programmed electrophysiological stimulation at baseline. Patients were then blindly randomized to receive either oral dofetilide 500 microg twice daily or oral sotalol 160 mg twice daily, for 3 to 5 days. Suppression of inducible ventricular tachycardia on the drug was then assessed by programmed electrophysiological stimulation. After a wash-out period of at least 2.5 days, the patients received the alternative treatment for 3 to 5 days. Suppression of inducible ventricular tachycardia on the alternate drug was again determined by programmed electrophysiological stimulation. Selection of long-term treatment was allocated blindly according to programmed electrophysiological stimulation results. During the acute phase, 128 patients received both dofetilide and sotalol. Sixty-s...Continue Reading

Citations

Mar 23, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Hugo Van HerendaelPaul Dorian
Feb 8, 2006·Postgraduate Medical Journal·M C S Hall, D M Todd
Nov 30, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·T Jared Bunch, Jeffrey L Anderson
Jun 1, 2013·Cardiology and Therapy·Eric S Williams, Mohan N Viswanathan
Oct 30, 2015·Expert Opinion on Pharmacotherapy·J William SchleiferWin-Kuang Shen
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
Oct 27, 2004·Expert Opinion on Drug Safety·Hanne ElmingChristian Torp-Petersen
Jun 10, 2008·Cardiology Clinics·L Brent Mitchell
Jan 15, 2009·Pacing and Clinical Electrophysiology : PACE·Ron D B SimonMichael R Gold
Oct 1, 2011·Journal of Cardiovascular Electrophysiology·Giselle A BaqueroMario D Gonzalez
Jun 5, 2003·Expert Opinion on Pharmacotherapy·Hanne ElmingChristian Torp-Petersen
Dec 23, 2003·Current Opinion in Cardiology·Mazhar H Khan
Aug 18, 2005·Current Cardiology Reports·Arnold Pinter, Paul Dorian
Nov 15, 2019·Acta Anaesthesiologica Scandinavica·Tomas GudbjartssonLars Peter Schoedt Riber
May 31, 2003·Journal of Cardiovascular Pharmacology·Giora AmitzurMichael Eldar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.